Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Orchestra BioMed Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 88 | 0 | 2 | 2 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 1 | 0 | 0 | 0 | NA |
Total Current Assets | 89 | 0 | 2 | 2 | NA |
Net Property & Equipment | 1 | 0 | 0 | 0 | NA |
Investments & Advances | 3 | 68 | 160 | 160 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 0 | 0 | 0 | NA |
Total Assets | 95 | 68 | 162 | 162 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 3 | 0 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 5 | 1 | 0 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 3 | 0 | 0 | 0 | NA |
Total Current Liabilities | 11 | 2 | 0 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 15 | 0 | 6 | 6 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 73 | 166 | 157 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 27 | 75 | 166 | 157 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 317 | 0 | 0 | 5 | NA |
Retained Earnings | -249 | -7 | -4 | 0 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 68 | -7 | -4 | 5 | NA |
Total Liabilities & Shareholder's Equity | 95 | 68 | 162 | 162 | NA |
Total Common Equity | 68 | -7 | -4 | 5 | 0 |
Shares Outstanding | 35.70 | 11.20 | 20.40 | 20.40 | NA |
Book Value Per Share | 1.91 | -0.62 | -0.19 | 0.25 | 0.00 |
Fiscal Year End for Orchestra BioMed Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 65 | 75 | 88 | 109 | 118 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 66 | 76 | 89 | 110 | 120 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 3 | 3 | 3 | 3 | 3 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 72 | 83 | 95 | 116 | 126 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 10 | 0 |
Accounts Payable | 6 | 3 | 3 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 4 | 5 | 4 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 3 | 3 | 4 | 4 |
Total Current Liabilities | 15 | 10 | 11 | 21 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 13 | 14 | 15 | 14 | 14 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 10 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 28 | 25 | 27 | 37 | 36 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 322 | 320 | 317 | 316 | 312 |
Retained Earnings | -278 | -262 | -249 | -236 | -223 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 44 | 57 | 68 | 80 | 89 |
Total Liabilities & Shareholder's Equity | 72 | 83 | 95 | 116 | 126 |
Total Common Equity | 44 | 57 | 68 | 80 | 89 |
Shares Outstanding | 35.70 | 35.70 | 35.70 | 35.70 | 35.70 |
Book Value Per Share | 1.24 | 1.60 | 1.91 | 2.23 | 2.51 |